IL159913A0 - Methods for preventing antipsychotic-induced weight gain - Google Patents
Methods for preventing antipsychotic-induced weight gainInfo
- Publication number
- IL159913A0 IL159913A0 IL15991302A IL15991302A IL159913A0 IL 159913 A0 IL159913 A0 IL 159913A0 IL 15991302 A IL15991302 A IL 15991302A IL 15991302 A IL15991302 A IL 15991302A IL 159913 A0 IL159913 A0 IL 159913A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- weight gain
- induced weight
- preventing
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30769301P | 2001-07-23 | 2001-07-23 | |
| PCT/US2002/023441 WO2003009853A1 (en) | 2001-07-23 | 2002-07-22 | Methods for preventing antipsychotic-induced weight gain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL159913A0 true IL159913A0 (en) | 2004-06-20 |
Family
ID=23190816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15991302A IL159913A0 (en) | 2001-07-23 | 2002-07-22 | Methods for preventing antipsychotic-induced weight gain |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6680310B2 (el) |
| EP (1) | EP1408981B1 (el) |
| JP (2) | JP2004537563A (el) |
| KR (1) | KR20040028942A (el) |
| CN (2) | CN1853722A (el) |
| AT (1) | ATE406166T1 (el) |
| AU (1) | AU2002319665B2 (el) |
| BR (1) | BR0211365A (el) |
| CA (1) | CA2454339C (el) |
| CY (1) | CY1108562T1 (el) |
| DE (1) | DE60228579D1 (el) |
| DK (1) | DK1408981T3 (el) |
| ES (1) | ES2312598T3 (el) |
| HK (1) | HK1061526A1 (el) |
| IL (1) | IL159913A0 (el) |
| MX (1) | MXPA04000692A (el) |
| NZ (1) | NZ530724A (el) |
| PT (1) | PT1408981E (el) |
| WO (1) | WO2003009853A1 (el) |
| ZA (1) | ZA200400444B (el) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2314103T3 (es) * | 2001-08-31 | 2009-03-16 | Corcept Therapeutics, Inc. | Metodo para inhibir deterioro cognitivo en adultos con sindrome de down. |
| NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| GB0400031D0 (en) | 2004-01-03 | 2004-02-04 | Univ Sheffield | Depression treatment |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| US20060211667A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of pregnane steroid derivatives for enhancing physical performance |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| US8198305B2 (en) * | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JP6516743B2 (ja) | 2013-11-25 | 2019-05-22 | コーセプト セラピューティクス， インコーポレイテッド | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
| US9943526B2 (en) | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
| US10413540B2 (en) | 2017-03-31 | 2019-09-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US11273166B2 (en) | 2017-06-13 | 2022-03-15 | Monash University | Methods and compositions for the treatment of obesity |
| NZ776354A (en) | 2018-12-19 | 2023-03-31 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113490496A (zh) | 2019-02-22 | 2021-10-08 | 科赛普特治疗学股份有限公司 | 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途 |
| AU2020239920A1 (en) * | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| WO2021119432A1 (en) * | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| EP4146173A4 (en) | 2020-05-06 | 2024-05-29 | Corcept Therapeutics Incorporated | FORMULATIONS OF PYRIMIDINE-CYCLOHEXYL-GLUCOCORTICOID RECEPTOR MODULATORS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757400B1 (fr) * | 1996-12-19 | 1999-12-17 | Hoechst Marion Roussel Inc | Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs |
| WO1998027986A1 (en) * | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| JP2001518509A (ja) * | 1997-10-06 | 2001-10-16 | ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ | グルココルチコイド関連機能不全に関連した精神病の処置のための方法。 |
| WO1999059596A1 (en) | 1998-05-15 | 1999-11-25 | The Board Of Trustees Of Leland Stanford Junior University | Glucocorticoid receptor antagonists for the treatment of dementia |
| WO2000071106A2 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treating weight gain |
-
2002
- 2002-07-22 NZ NZ530724A patent/NZ530724A/en not_active IP Right Cessation
- 2002-07-22 EP EP02750269A patent/EP1408981B1/en not_active Expired - Lifetime
- 2002-07-22 ES ES02750269T patent/ES2312598T3/es not_active Expired - Lifetime
- 2002-07-22 DE DE60228579T patent/DE60228579D1/de not_active Expired - Lifetime
- 2002-07-22 AU AU2002319665A patent/AU2002319665B2/en not_active Ceased
- 2002-07-22 MX MXPA04000692A patent/MXPA04000692A/es active IP Right Grant
- 2002-07-22 PT PT02750269T patent/PT1408981E/pt unknown
- 2002-07-22 CN CNA2005101236436A patent/CN1853722A/zh active Pending
- 2002-07-22 CA CA2454339A patent/CA2454339C/en not_active Expired - Fee Related
- 2002-07-22 US US10/201,356 patent/US6680310B2/en not_active Expired - Lifetime
- 2002-07-22 KR KR10-2004-7001039A patent/KR20040028942A/ko not_active Application Discontinuation
- 2002-07-22 IL IL15991302A patent/IL159913A0/xx not_active IP Right Cessation
- 2002-07-22 JP JP2003515245A patent/JP2004537563A/ja active Pending
- 2002-07-22 DK DK02750269T patent/DK1408981T3/da active
- 2002-07-22 BR BR0211365-1A patent/BR0211365A/pt not_active Application Discontinuation
- 2002-07-22 WO PCT/US2002/023441 patent/WO2003009853A1/en active IP Right Grant
- 2002-07-22 AT AT02750269T patent/ATE406166T1/de active
- 2002-07-22 CN CNA028166647A patent/CN1547473A/zh active Pending
-
2004
- 2004-01-21 ZA ZA2004/00444A patent/ZA200400444B/en unknown
- 2004-06-21 HK HK04104474A patent/HK1061526A1/xx not_active IP Right Cessation
-
2008
- 2008-11-12 CY CY20081101296T patent/CY1108562T1/el unknown
-
2009
- 2009-02-03 JP JP2009023156A patent/JP2009102413A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1547473A (zh) | 2004-11-17 |
| EP1408981A1 (en) | 2004-04-21 |
| ATE406166T1 (de) | 2008-09-15 |
| CY1108562T1 (el) | 2014-04-09 |
| EP1408981B1 (en) | 2008-08-27 |
| CN1853722A (zh) | 2006-11-01 |
| CA2454339C (en) | 2012-01-10 |
| JP2004537563A (ja) | 2004-12-16 |
| AU2002319665B2 (en) | 2006-09-21 |
| CA2454339A1 (en) | 2003-02-06 |
| BR0211365A (pt) | 2004-09-21 |
| ZA200400444B (en) | 2005-03-30 |
| EP1408981A4 (en) | 2005-06-08 |
| MXPA04000692A (es) | 2004-04-21 |
| KR20040028942A (ko) | 2004-04-03 |
| US20030027802A1 (en) | 2003-02-06 |
| DE60228579D1 (de) | 2008-10-09 |
| JP2009102413A (ja) | 2009-05-14 |
| NZ530724A (en) | 2005-09-30 |
| ES2312598T3 (es) | 2009-03-01 |
| HK1061526A1 (en) | 2004-09-24 |
| US6680310B2 (en) | 2004-01-20 |
| PT1408981E (pt) | 2008-12-04 |
| WO2003009853A1 (en) | 2003-02-06 |
| DK1408981T3 (da) | 2009-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108562T1 (el) | Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες | |
| IL139672A (en) | Glucocorticoid receptor antagonists for the tretment of dementia | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| CA2302586A1 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| HK1068783A1 (en) | Methods for increasing the therapeutic response to electroconvulsive therapy ("ect") | |
| TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
| IL160649A0 (en) | Methods for inhibiting cognitive deterioration in adults with down syndrome | |
| TWI318879B (en) | Powdered mixture of plant sterol and emulsifier and preparation thereof | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| IL158744A0 (en) | Methods for treating delirium using glucocorticoid receptor-specific antagonists | |
| AU2003231019A8 (en) | Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use | |
| NO20023841D0 (no) | Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn | |
| IL149357A0 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| HUP0303500A2 (hu) | Eljárás szexuális rendellenességek kezelésére bombezin-antagonisták segítségével | |
| EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |